IM-250

IM-250 is an anti-herpetic drug candidate developed by Innovative Molecules Gmbh. The drug was conceived by a chemist at the company, who hypothesized that swapping the sulfonamide function group on pritelivir for a sulfoximine would reduce off-target effects. Chemists at the company also tweaked an aromatic group on pritelivir to make their drug candidate more likely to enter the central nervous system, where it could go after latent HSV.

Innovative Molecules is trying to raise 20 million euro for a clinical trial on humans.